
    
      This is an observational, international, multicenter study planned to be conducted in RMS
      subjects using the RebiSmart auto-injector at 300 sites in 15 countries across Europe. The
      participating countries are Austria, Belgium, Czech Republic, Denmark, Estonia, France,
      Germany, Hungary, Lithuania, Portugal, Slovakia, Sweden, Switzerland, the Netherlands and the
      United Kingdom. Subjects with RMS na√Øve to treatment or currently being treated with Rebif
      multi-dose injected by RebiSmart for no more than 6 weeks and meeting the eligibility
      criteria will receive Rebif 22 or 44 mcg subcutaneously three time a week. The dose of Rebif
      will be titrated during the initial four weeks of treatment. The planned observational period
      per subject is 12 months. The study visits comprises of: Baseline or Day 1 (Visit 1), Month 6
      (Visit 2), and Month 12 (Visit 3).

      OBJECTIVES

      Primary objective:

        -  To assess adherence to treatment in subjects with RMS using RebiSmart to self-inject
           Rebif in a multi-dose cartridge

      Secondary objectives:

        -  To assess effectiveness and convenience of treatment in subjects with RMS using
           RebiSmart to self-inject Rebif in a multi-dose cartridge.
    
  